Skip to main content
Caplight Logo









UbiquiTx

UbiquiTx

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://ubiquitx.com/

Last Round

Grant

Aug 15, 2025

Total Funding Raised

$1.63M

Company Overview

UbiquiTx is a biotechnology company that develops an AI-native platform for programmable modulation of the proteome to create targeted protein degradation therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

proteome editingprotein degradationtargeted protein modulationundruggable proteinschimeric ligands for induced proximityCLIPsAI drug discoveryprotein language modelsgenerative biologytherapeutic designpeptide binderstarget de-riskingbiotech platformdrug discovery platformSBIR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

UbiquiTx Comparables

Compare UbiquiTx with similar companies based on industry and business-model similarity.

UbiquiTx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Celeris Therapeutics
80%
Avilar Therapeutics
77%
Magnet Biomedicine
77%

UbiquiTx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 15, 2025
AcceleratorNov 21, 2024
GrantJul 15, 2024
GrantJul 10, 2024
GrantMar 1, 2024

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 15, 2025

    $391K grant received from NIAAA.

  • Nov 21, 2024

    Merck & Co., Inc. and Northpond Ventures participated in the round.

UbiquiTx Filings

Explore SEC and related filing metadata, where available.

UbiquiTx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about UbiquiTx's valuation, stock price, and market status.

Is UbiquiTx a public or private company?

UbiquiTx is a private company.

What is the current stock price of UbiquiTx?

UbiquiTx is a private company with no public stock price. Caplight tracks UbiquiTx's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is UbiquiTx worth (valuation)?

Valuation information for UbiquiTx is not publicly available.

Can I buy UbiquiTx stock?

UbiquiTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was UbiquiTx's last funding round?

UbiquiTx's most recent funding round was Grant on August 15, 2025.

Who are the main investors in UbiquiTx?

Key investors in UbiquiTx include National Cancer Institute, National Institute of Allergy and Infectious Diseases, Northpond Ventures, McKesson Ventures, National Institute on Alcohol Abuse and Alcoholism.

Will UbiquiTx IPO soon?

No public IPO plans have been announced for UbiquiTx.

How can I track UbiquiTx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor UbiquiTx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range2
Year Founded2021
Last FundingAug 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?